Bär & Karrer advised Lalique Group on Silvio Denz’s – its majority shareholder – public tender offer for its publicly held registered shares. On 30 May 2024, Silvio Denz and Lalique entered into a transaction agreement regarding
Tags :Bär & Karrer
Bär & Karrer advises funds managed by Equistone on the sale of KWC Group’s home division, a designer and manufacturer of kitchen, bathroom and washroom fittings and accessories, to Paini Rubinetterie. Bär &
Advestra advised Cactus life sciences, a global scientific communications agency that works with blue chip pharma and biotechnology companies, on nspm and eluSCIdate’
Bär & Karrer and Willkie Farr & Gallagher advised PAI Partners (PAI) on the acquisition of Vamed Group’s rehabilitation business (VAMED) from Fresenius, advised by NKF and Latham & Watkins. PAI will become
EGS Beteiligungen AG (EGSB) acquired a majority stake in the SERTO Group, a specialist in the field of tube fittings and pipe connection components. The management of the SERTO Group remains invested. Bär &
The German Amapharm, a global leader in vitamin gummies, has acquired its long-standing bulk supplier, F. Hunziker + Co, from the founding family. F. Hunziker + Co, headquartered in Dietikon, Switzerland, is a traditional family business specializing
Aunetic, formerly Blika, a portfolio company of Main Capital and leading provider of governance software, has acquired all shares in LARI digital, a leading software provider that offers a cloud-based platform for legal and regulatory
Tertianum group, a renowned player for elderly care and assisted living in Switzerland, which forms part of the Swiss investment firm Capvis, has acquired the elderly care and nursing home group Reliva. The Reliva group
Bär & Karrer has announced the appointment of its partner Daniel Leu as Co-Head of law firm’s Private Clients Team. Daniel Leu will lead the Private Clients Team together with Tina Wüstemann.
AC Immune, a Swiss clinical stage biopharmaceutical company pioneering in precision medicine for neurodegenerative diseases listed on the Nasdaq completed an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per
